Viking Therapeutics, Inc.
http://www.vikingtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Viking Therapeutics, Inc.
Roche Could Have The Best Obesity Pill
That is, if very early data in a handful of patients are borne out in later, larger studies.
Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data
Survodutide burnishes its best-in-class MASH case with a 64% improvement in moderate-to advanced fibrosis at Phase II, but tolerability an issue
EASL: Tirzepatide Is The One To Beat In MASH
An important mid-stage trial succeeds, but an odd finding on the fibrosis endpoint will spur close examination of Lilly’s incretin.
Viking Bolsters MASH Case With 52-Week Histology Data
Viking will look to plan a Phase III program with the FDA after showing 52-week success on MASH resolution and fibrosis reduction with VK2809. The firm still hopes to move forward with a partner.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice